Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 71%: Here's is How to TradeZacks Investment Research • 11/24/22
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™GlobeNewsWire • 11/16/22
Moore Kuehn, PLLC Encourages Investors of Vir Biotechnology, Inc. to Contact Law FirmNewsfile Corp • 11/15/22
Wall Street Analysts Predict a 107% Upside in Vir Biotechnology, Inc. (VIR): Here's What You Should KnowZacks Investment Research • 11/08/22
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) InfectionGlobeNewsWire • 11/06/22
Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit GrowthInvestors Business Daily • 11/04/22
Vir Biotechnology, Inc. (VIR) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research • 11/03/22
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/03/22
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD's The Liver Meeting® 2022GlobeNewsWire • 10/31/22
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022GlobeNewsWire • 10/28/22
Vir begins dosing participants in Phase 2 clinical trial for new type of flu shotMarket Watch • 10/18/22
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza AGlobeNewsWire • 10/18/22
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) ConferenceGlobeNewsWire • 10/11/22
The Next Pandemic? Vir Biotechnology Just Signed A $1 Billion Deal To Work On ItInvestors Business Daily • 10/04/22
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease ThreatsGlobeNewsWire • 10/04/22
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus InfectionGlobeNewsWire • 09/22/22
Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceGlobeNewsWire • 09/06/22